Amygdalin alleviates psoriasis-like lesions by improving skin barrier function

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Psoriasis is a chronic inflammatory skin disease driven by immune system dysregulation.
• Amygdalin exhibits known immune-modulating and anti-inflammatory properties.
• Understanding amygdalin's therapeutic potential for psoriasis requires investigation into its effects on disease pathogenesis.

Purpose of the Study:

• To evaluate the efficacy of amygdalin in preclinical models of psoriasis.
• To investigate amygdalin's impact on skin barrier function and inflammatory pathways.
• To explore the underlying molecular mechanisms of amygdalin's action in psoriasis.

Main Methods:

• Animal models: Imiquimod-induced psoriasis and tape-stripping-induced skin barrier disruption.
• In vitro studies: Investigating amygdalin's effects on HaCaT cells stimulated with IL-17A and TNF-α.
• Molecular analysis: Assessing inflammatory cytokine production (IL-1β, IL-6, TNF-α) and skin barrier protein expression (filaggrin, involucrin, keratin10).
• Mechanistic study: Examining the p38MAPK signaling pathway.

Main Results:

• Amygdalin treatment reduced epidermal thickness and inflammatory cell infiltration in vivo.
• Amygdalin inhibited key pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and enhanced skin barrier proteins (filaggrin, involucrin, keratin10) in both animal models and cell cultures.
• Amygdalin suppressed the phosphorylation of the p38MAPK signaling pathway.

Conclusions:

• Amygdalin effectively alleviates psoriasis-like skin lesions and improves impaired skin barrier function.
• The therapeutic effects of amygdalin involve the modulation of inflammatory responses and restoration of skin barrier integrity.
• Amygdalin shows promise as a potential therapeutic agent for psoriasis, warranting further clinical development.